.avif)
UPA/PAI-1 Test - Breast Cancer Biomarker
Measures uPA and PAI‑1 levels to evaluate your body's clot‑breaking (fibrinolytic) balance and related inflammation. Results can reveal elevated risk for blood clots, cardiovascular disease, metabolic syndrome/insulin resistance and offer prognostic information in some cancers so you can take earlier preventive or treatment actions.
MammaPrint Test - 70-Gene Breast Cancer Biomarker Panel
MammaPrint is a genomic test that analyzes the activity of 70 genes in early-stage breast tumors to predict a patient’s risk of cancer recurrence. By distinguishing low- from high-risk disease, it helps patients and doctors avoid unnecessary chemotherapy and its side effects or choose more aggressive treatment to lower recurrence risk.
CA 27-29 Test - Breast Cancer Biomarker
The CA 27‑29 blood test measures a tumor marker linked to breast cancer to monitor disease activity and treatment response. Detecting rising levels early can prompt timely intervention and may help reduce the risk of advanced or metastatic disease.
Oncotype DX Breast Cancer Test - 21-Gene Biomarker Panel
Oncotype DX is a genomic test run on early-stage, ER-positive breast tumor tissue that predicts your risk of recurrence and whether you’re likely to benefit from chemotherapy. By identifying patients who won’t gain meaningful benefit from chemo, it can help you avoid unnecessary chemotherapy and its short- and long-term side effects.
Ki-67 Test - Breast Cancer Biomarker
The Ki‑67 test measures how quickly abnormal cells are dividing, giving doctors a clear marker of tumor aggressiveness to help guide treatment decisions. Early insight into proliferation can prompt timely, appropriate therapy and monitoring—potentially reducing the risk of under‑ or overtreatment.
CA 15-3 Test - Breast Cancer Biomarker
CA 15-3 is a blood test that measures a tumor marker used to monitor breast cancer treatment and detect recurrence or progression. Regular CA 15-3 testing can alert you and your clinician to changes sooner, enabling earlier intervention that may help avoid more advanced disease and complications.
PIK3CA Mutation Test - Breast Cancer Biomarker
A rapid molecular test that detects mutations in the PIK3CA gene, which are linked to several cancers (notably breast, colorectal and endometrial). Knowing your PIK3CA status can guide risk assessment and targeted treatment decisions—potentially enabling earlier intervention and therapies that reduce the risk of disease progression.
BRCA3 Gene Test - Breast Cancer Biomarker
This test screens for harmful variants in PALB2 (sometimes called “BRCA3”) to identify an inherited increase in breast‑cancer risk and clarify family cancer susceptibility. Knowing your result lets you pursue earlier surveillance, risk‑reducing strategies, and personalized care to help prevent or detect breast cancer sooner; PALB2-related risk patterns are similar to BRCA2 and aren’t strongly linked to ovarian cancer.
HER2 Test - Breast Cancer Biomarker
This HER2 test determines whether a tumor overexpresses the HER2 protein or has HER2 gene amplification to identify eligibility for HER2‑targeted therapies. Early, accurate HER2 detection helps avoid ineffective treatments and can reduce the risk of cancer progression and recurrence.
Progesterone Receptor (PR) Test - Breast Cancer Biomarker
The Progesterone receptor (PR) test checks whether tumor cells (most commonly in breast cancer) express progesterone receptors to determine hormone sensitivity and guide personalized treatment choices. Knowing PR status helps avoid ineffective therapies and supports selecting appropriate endocrine treatment to reduce the risk of cancer recurrence.
Estrogen Receptor (ER) Test - Breast Cancer Biomarker
The Estrogen Receptor (ER) test checks whether tumor cells—most commonly in breast cancer—have receptors for estrogen, which determines if hormone (endocrine) therapies are likely to be effective. Knowing ER status helps guide targeted treatment choices, reducing the risk of cancer progression, recurrence, and unnecessary or ineffective therapies.
.svg)
